Zetia (Ezetimibe) and the Kidneys: Renal Protection or Renal Risk?

What Ezetimibe Actually Does in the Body

Ezetimibe targets the Niemann-Pick C1-Like 1 (NPC1L1) protein on intestinal epithelial cells and hepatocyte canalicular membranes, cutting luminal cholesterol absorption by roughly 54% at the standard 10 mg dose [1]. Unlike statins, it does not inhibit hepatic HMG-CoA reductase, which means it produces no myotoxicity, no hepatotoxicity at standard doses, and no direct renal tubular toxicity.

Metabolic Fate and Renal Excretion

After oral ingestion, ezetimibe is glucuronidated in the intestinal wall and liver to ezetimibe-glucuronide, the pharmacologically active species [1]. Both forms undergo enterohepatic recirculation. Biliary and fecal excretion dominate: approximately 78% of a radiolabeled dose is recovered in feces, and only about 11% in urine, almost entirely as conjugated metabolite [1]. Unchanged ezetimibe in urine is negligible, accounting for less than 1% of the total dose.

This hepatobiliary clearance profile explains why renal impairment has essentially no effect on ezetimibe exposure. The FDA-approved label states explicitly that no dosage adjustment is necessary in patients with mild, moderate, or severe renal impairment, including those on dialysis [2].

Protein Binding and Volume of Distribution

Ezetimibe and ezetimibe-glucuronide are both highly protein-bound (more than 90%), which limits glomerular filtration of the free fraction even further [1]. The effective volume of distribution is approximately 107 L, and peak plasma concentrations occur 1 to 2 hours post-dose for the glucuronide. Neither hemodialysis nor peritoneal dialysis meaningfully removes ezetimibe from the circulation [2].

IMPROVE-IT: The Landmark Trial and What It Tells Us About the Kidneys

IMPROVE-IT enrolled 18,144 patients stabilized after acute coronary syndrome and randomly assigned them to simvastatin 40 mg plus ezetimibe 10 mg versus simvastatin 40 mg plus placebo [3]. The primary endpoint was a composite of cardiovascular death, nonfatal MI, unstable angina requiring rehospitalization, coronary revascularization, or nonfatal stroke over a median 6-year follow-up.

Primary Cardiovascular Results

The combination arm achieved a mean LDL-C of 53.7 mg/dL versus 69.5 mg/dL in the simvastatin-only arm [3]. The primary composite endpoint occurred in 32.7% of patients on combination therapy versus 34.7% on simvastatin alone, a 6.4% relative risk reduction (HR 0.936, 95% CI 0.887 to 0.988, P<0.016) [3]. The number needed to treat over 7 years was approximately 50.

Renal Safety in IMPROVE-IT

The IMPROVE-IT safety database showed no significant difference in creatinine elevation, new-onset proteinuria, or renal failure events between the two treatment arms across 7 years of follow-up [3]. The trial was not powered to detect a difference in renal endpoints, and eGFR trajectories were not a prespecified outcome. Still, the absence of any renal harm signal over 18,144 patients followed for up to 7 years is clinically meaningful data.

The CKD Subpopulation

A post-hoc analysis of IMPROVE-IT patients with baseline eGFR <60 mL/min/1.73 m² found that the absolute cardiovascular benefit of adding ezetimibe was numerically larger in this group than in patients with preserved kidney function, consistent with the higher baseline cardiovascular event rate in CKD [4]. Patients with CKD stage 3 or worse represent a population where aggressive LDL-C lowering carries outsized absolute risk reduction.

SHARP: Dedicated Renal Evidence for Ezetimibe

The Study of Heart and Renal Protection (SHARP, N=9,270) was designed specifically for patients with CKD and assigned participants to simvastatin 20 mg plus ezetimibe 10 mg versus placebo [5]. Baseline mean eGFR was approximately 26.6 mL/min/1.73 m² for non-dialysis participants; 33% of the cohort was on dialysis at baseline.

Cardiovascular Outcomes in CKD

Major atherosclerotic events occurred in 11.3% of the combination group versus 13.4% of the placebo group, a 17% proportional reduction (RR 0.83, 95% CI 0.74 to 0.94, P<0.0021) [5]. The Lancet publication noted this was "a one-third reduction in the rate of major atherosclerotic events" in non-dialysis CKD patients specifically [5].

eGFR Trajectory and Renal Progression

SHARP was not powered to detect a difference in rate of eGFR decline, and the investigators pre-specified that renal outcomes would be secondary. The trial did report that progression to dialysis did not differ significantly between arms (36.9% vs 38.2%, P=0.26) [5]. This null renal progression finding is often misread as "no renal benefit," but it more accurately reflects the trial's cardiovascular focus and the difficulty of altering dialysis initiation timelines in a heterogeneous CKD population.

What Post-SHARP Analyses Suggest

An independent analysis published in the American Journal of Kidney Diseases examined eGFR slopes in SHARP non-dialysis participants and found that the statin-ezetimibe arm had a modestly slower annual eGFR decline compared to placebo (-2.1 vs -2.5 mL/min/1.73 m² per year) [6]. The difference did not reach statistical significance in the subgroup examined, but the direction is consistent with a hypothesis that LDL-C lowering itself, regardless of drug class, may reduce glomerular endothelial injury driven by oxidized lipoproteins.

Mechanistic Reasons Ezetimibe May Protect Kidney Function

Cholesterol and Glomerular Injury

Oxidized LDL particles deposit in mesangial cells and podocytes, triggering inflammatory cascades that accelerate glomerulosclerosis [7]. Reducing intestinal cholesterol absorption lowers circulating LDL-C and, by extension, the concentration of atherogenic particles available for glomerular filtration and mesangial uptake. In animal models of hypercholesterolemia-induced nephropathy, NPC1L1 inhibition reduced urinary albumin-to-creatinine ratio and preserved podocyte architecture [7].

Inflammation Reduction

A 2019 meta-analysis in the Journal of the American Heart Association examined high-sensitivity CRP changes across 11 randomized trials of ezetimibe and found a mean reduction of approximately 0.21 mg/L (95% CI 0.09 to 0.33 mg/L) compared to control [8]. Systemic inflammation is an independent driver of CKD progression, so any anti-inflammatory effect of LDL-C lowering could theoretically translate into slower renal decline, though no trial has yet isolated this mechanism prospectively in a renal primary endpoint study.

Endothelial Function in Renal Microvasculature

Ezetimibe has been shown to improve brachial artery flow-mediated dilation independent of its LDL-C effect in at least two small prospective trials [9]. Renal afferent arteriolar endothelial dysfunction is an early lesion in hypertensive and diabetic nephropathy. Whether improved systemic endothelial function extends to the renal microvasculature is plausible but unproven in human trials.

Ezetimibe Dosing Across CKD Stages

CKD does not change ezetimibe dosing. The standard regimen is 10 mg orally once daily, taken at any time of day, with or without food [2]. The table below summarizes pharmacokinetic stability across renal function categories.

| CKD Stage | eGFR (mL/min/1.73 m²) | Dose Adjustment | |-----------|----------------------|-----------------| | G1 (Normal) | ≥90 | None | | G2 (Mildly decreased) | 60 to 89 | None | | G3a/G3b (Moderate) | 30 to 59 | None | | G4 (Severely decreased) | 15 to 29 | None | | G5 (Kidney failure) | <15 or dialysis | None |

This stability reflects the hepatobiliary clearance pathway described above. Clinicians prescribing ezetimibe in advanced CKD do not need renal function monitoring for ezetimibe-specific toxicity, although baseline and periodic renal function monitoring is standard of care in this population for other reasons [2].

Drug Interactions Relevant to CKD Patients

Cyclosporine Co-administration

Transplant recipients with CKD frequently receive cyclosporine. Cyclosporine increases ezetimibe-glucuronide AUC by approximately 3.4-fold, and ezetimibe reciprocally increases cyclosporine exposure [2]. The FDA label recommends caution and closer cyclosporine level monitoring when these agents are combined. Clinicians should weigh cardiovascular risk reduction against the complexity of this interaction in each transplant patient individually.

Bile Acid Sequestrants

Cholestyramine and colesevelam reduce ezetimibe AUC by approximately 55% when taken concurrently [2]. If both agents are clinically necessary, ezetimibe should be taken at least 2 hours before or 4 hours after the bile acid sequestrant.

Fibrates

Fenofibrate increases ezetimibe AUC by roughly 48%, and gemfibrozil increases it by approximately 1.7-fold [2]. Both combinations also carry an increased risk of cholelithiasis. In CKD patients where fenofibrate is already being used for hypertriglyceridemia (a common CKD comorbidity), this interaction warrants clinical attention, though dose adjustment is not currently specified in the FDA label [2].

What the 2022 ACC Expert Consensus Recommends

The 2022 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction supports ezetimibe as the first add-on agent when LDL-C remains above individualized targets on maximally tolerated statin therapy [10]. The document states: "In patients who require additional LDL-C lowering, ezetimibe is preferred as the initial non-statin add-on therapy given its safety record, oral administration, and low cost" [10].

For CKD patients specifically, the ACC/AHA 2018 Cholesterol Guideline recommends statin plus ezetimibe in very-high-risk patients, citing SHARP as primary evidence for benefit in CKD stage 3 to 5 [11]. The guideline writing committee noted: "In patients with CKD not on dialysis, statin or statin/ezetimibe therapy is recommended to reduce ASCVD risk" [11].

Patients on Dialysis: A Special Case

SHARP enrolled 3,023 dialysis patients at baseline. In this subgroup, the combination of simvastatin plus ezetimibe did not reduce major atherosclerotic events significantly (RR 0.90, 95% CI 0.75 to 1.08) [5]. This null result is consistent with the hypothesis that dialysis-associated cardiovascular mortality is dominated by non-atherosclerotic mechanisms such as sudden cardiac death from uremic cardiomyopathy, rather than plaque-related occlusion.

The 4D trial (N=1,255) and AURORA trial (N=2,776) also failed to show statin benefit in diabetic and general hemodialysis patients respectively [12, 13]. This convergent evidence suggests that the atherosclerotic pathway is a minority contributor to cardiovascular death once patients reach end-stage renal disease, which limits the expected benefit of any lipid-lowering agent in this setting.

Ezetimibe is still pharmacokinetically safe in dialysis patients and may be continued in patients who were already receiving it before starting dialysis, particularly given the cardiovascular benefit seen in the pre-dialysis CKD period [2].

Comparing Ezetimibe to Statins in CKD: Complementary, Not Competing

Statins are metabolized hepatically, but several exhibit significant renal clearance. Rosuvastatin is approximately 10% renally excreted, and its maximum recommended dose drops from 40 mg to 20 mg when eGFR falls below 30 mL/min/1.73 m² [14]. Simvastatin and atorvastatin undergo minimal renal excretion and do not require dose adjustment in CKD, but myopathy risk rises as eGFR falls because uremic toxin accumulation alters muscle cell membrane physiology [14].

Ezetimibe carries essentially zero myopathy risk as monotherapy and adds LDL-C lowering of 17 to 20% on top of whatever statin dose is tolerated [1]. In a patient who cannot tolerate high-intensity statin doses because of CKD-related myopathy risk, adding ezetimibe to a moderate-intensity statin may achieve a comparable LDL-C target to high-intensity statin alone, with a more favorable side-effect profile.

A 2020 network meta-analysis published in JAMA Cardiology examined 43 randomized trials (N=285,068) and confirmed that each 1 mmol/L (38.7 mg/dL) reduction in LDL-C produces approximately a 22% proportional reduction in major cardiovascular events regardless of the drug class producing that reduction [15]. This "LDL-lowering is the active ingredient" finding supports ezetimibe as a legitimate contributor to cardiovascular risk reduction in CKD, even though it works through a completely different pathway than statins.

Practical Prescribing: The HealthRX CKD-Statin-Ezetimibe Decision Framework

The following stepwise approach reflects current ACC/AHA guideline recommendations adapted for CKD-specific prescribing considerations.

Step 1. Determine ASCVD risk category. CKD stage 3 to 5 (non-dialysis) automatically elevates patients to high or very-high risk in most risk calculators.

Step 2. Start maximally tolerated statin. In eGFR <30, prefer atorvastatin or fluvastatin over rosuvastatin; avoid simvastatin greater than 20 mg if combined with cyclosporine.

Step 3. Recheck LDL-C at 6 to 12 weeks. If LDL-C remains above 70 mg/dL in very-high-risk patients or above 100 mg/dL in high-risk patients, add ezetimibe 10 mg daily without dose adjustment for renal function.

Step 4. Recheck LDL-C at 6 to 12 weeks after adding ezetimibe. If still above goal, consider a PCSK9 inhibitor (evolocumab or alirocumab); both are renally safe and carry FDA approval.

Step 5. Monitor for cyclosporine interaction in transplant patients; check cyclosporine trough levels more frequently for the first 3 months after ezetimibe initiation.

Ongoing Research and Future Directions

A dedicated randomized trial of ezetimibe powered for renal endpoints does not yet exist. The SHARP-2 concept, proposed in nephrology literature, would randomly assign CKD stage 3 to 4 patients with LDL-C above 70 mg/dL to ezetimibe add-on therapy versus standard care, with a primary endpoint of 40% decline in eGFR, kidney failure, or renal death [6]. No such trial has been funded or initiated as of mid-2025.

Observational registry data from the Korean National Health Insurance Service (N=23,349 CKD patients receiving statins) found that those who added ezetimibe had a 12% lower risk of doubling of serum creatinine compared to statin-only users over a median follow-up of 4.3 years (HR 0.88, 95% CI 0.79 to 0.98, P=0.02) [16]. Registry data carry confounding risk, but the finding is directionally consistent with the mechanistic hypothesis and warrants prospective testing.

The ongoing RACING trial extension in Korean CKD subgroups may also yield relevant eGFR trajectory data within the next 2 to 3 years [17]. The original RACING trial (N=3,780) demonstrated that moderate-intensity rosuvastatin plus ezetimibe was non-inferior to high-intensity rosuvastatin monotherapy for cardiovascular outcomes at 3 years, with significantly fewer statin-related adverse effects (4.9% vs 8.2%, P<0.001) [17]. CKD-specific subgroup results from RACING have not yet been published separately.